MedTrace Logo

OPTImal PALliative Anti-epidermal Growth Factor Receptor Treatment in Metastatic Colorectal Cancer -

NCT03750175 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 49

Last updated 2023-02-03

No results posted yet for this study

Summary

The present study will investigate the feasibility and clinical value of using circulating tumor DNA as selection for anti-epidermal growth factor receptor treatment for metastatic colorectal cancer.

Conditions

  • Colorectal Cancer Metastatic
  • Circulating Tumor DNA
  • KRAS Gene Mutation
  • NRAS Gene Mutation
  • BRAF Gene Mutation
  • Epidermal Growth Factor Receptor Inhibitor

Interventions

OTHER

Plasma circulating DNA analysis

Clinical utility of ctDNA analysis for treatment decision

Sponsors & Collaborators

  • Karen-Lise Garm Spindler

    lead OTHER

Principal Investigators

  • Karen-Lise G Spindler · Department of Oncology, AUH, Dk

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2022-06-01
Completion
2022-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03750175 on ClinicalTrials.gov